Innovent Reports First Patient Dosing of IBI343 in P-I Study for the Treatment of Advanced Solid Tumors
Shots:
- The first patient has been dosed in Australia in the P-I clinical trial evaluating the safety, tolerability & preliminary efficacy of IBI343 in patients with advanced solid tumors. The study also determines the MTD & RP2D
- In both Claudin 18.2 high and low expression mice tumor-bearing models, the therapy showed a potent tumor growth inhibition efficacy and showed a tolerable safety profile in preclinical in vivo models along with a promising anti-tumor effect
- IBI343 is a recombinant human anti-Claudin 18.2 monoclonal ADC that binds to the Claudin 18.2-expressing tumor cells. The therapy was developed by Innovent Biologics
Ref: PRNewswire | Image: Innovent
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
